Skip to main content
Log in

The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

  • Original Paper
  • Published:
JBIC Journal of Biological Inorganic Chemistry Aims and scope Submit manuscript

Abstract

An investigation of the molecular mechanism of the anticancer activity demonstrated by the ruthenium(II)–arene compound [Ru(η6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed “RAPTA-C”, in Ehrlich ascites carcinoma (EAC) bearing mice is described. RAPTA-C exhibits effective cell growth inhibition by triggering G2/M phase arrest and apoptosis in cancer cells. Cell cycle arrest is associated with increased levels of p21 and reduced amounts of cyclin E. RAPTA-C treatment also enhances the levels of p53, and its treatment triggers the mitochondrial apoptotic pathway, as shown by the change in Bax to Bcl-2 ratios, resulting in cytochrome c release and caspase-9 activation. c-Jun NH2-terminal kinase (JNK) is a critical mediator in RAPTA-C-induced cell growth inhibition. Activation of JNK by RAPTA-C increases significantly during apoptosis. Overall, these results suggest a critical role for JNK and p53 in RAPTA-C-induced G2/M arrest and apoptosis of EAC-bearing mice. Consequently, RAPTA-C treatment results in a significant inhibition in the progression of cancer in an animal model, which emulates the human disease, and does so with remarkably low general toxicity; hence, RAPTA-C has potential for clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Reedijk J (1987) Pure Appl Chem 59:181–192

    Article  CAS  Google Scholar 

  2. Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK (2008) Dalton Trans 183–194

  3. Wong E, Giandomenico CM (1999) Chem Rev 99:2451–2466

    Article  PubMed  CAS  Google Scholar 

  4. Zanzi I, Srivastava SC, Meinken GE, Robeson W, Mausner LF, Fairchild RG, Margouleff D (1989) Nucl Med Biol 16:397–403

    CAS  Google Scholar 

  5. Srivastava SC (1996) Semin Nucl Med 26:119–131

    Article  PubMed  CAS  Google Scholar 

  6. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH (2004) Clin Cancer Res 10:3717–3727

    Article  PubMed  CAS  Google Scholar 

  7. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK (2006) J Inorg Biochem 100:891–904

    Article  PubMed  CAS  Google Scholar 

  8. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK (2008) Chem Biodivers (in press)

  9. Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M, Jakupec MA, Keppler BK (2006) Dalton Trans 1796–1802

  10. Jakupec MA, Reisner E, Eichinger A, Pongratz M, Arion VB, Galanski M, Hartinger CG, Keppler BK (2005) J Med Chem 48:2831–2837

    Article  PubMed  CAS  Google Scholar 

  11. Allardyce CS, Dyson PJ (2001) Platinum Metals Rev 45:62–69

    CAS  Google Scholar 

  12. Clarke MJ (2003) Coord Chem Rev 236:209–232

    Article  CAS  Google Scholar 

  13. Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G (2005) J Anal At Spectrom 20(9):856–863

    Article  CAS  Google Scholar 

  14. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK (2006) Chem Rev 106:2224–2248

    Article  PubMed  CAS  Google Scholar 

  15. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI (2002) Br J Cancer 86:1652–1657

    Article  PubMed  CAS  Google Scholar 

  16. Galeano A, Berger MR, Keppler BK (1992) Arzneimittelforschung 42:821–824

    PubMed  CAS  Google Scholar 

  17. Berger MR, Garzon FT, Keppler BK, Schmähl D (1989) Anticancer Res 9:761–765

    PubMed  CAS  Google Scholar 

  18. Sava G, Bergamo A (2000) Int J Oncol 17:353–365

    PubMed  CAS  Google Scholar 

  19. Seelig MH, Berger MR, Keppler BK (1992) J Cancer Res Clin Oncol 118:195–200

    Article  PubMed  CAS  Google Scholar 

  20. Frasca DR, Gehrig LE, Clarke MJ (2001) J Inorg Biochem 83:139–149

    Article  PubMed  CAS  Google Scholar 

  21. Kratz F, Hartmann M, Keppler B, Messori L (1994) J Biol Chem 269:2581–2588

    PubMed  CAS  Google Scholar 

  22. Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG, Allmaier G, Keppler BK (2004) J Anal At Spectrom 19:46–51

    Article  CAS  Google Scholar 

  23. Polec-Pawlak K, Abramski JK, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK, Jarosz M (2006) Electrophoresis 27:1128–1135

    Article  PubMed  CAS  Google Scholar 

  24. Piccioli F, Sabatini S, Messori L, Orioli P, Hartinger CG, Keppler BK (2004) J Inorg Biochem 98:1135–1142

    Article  PubMed  CAS  Google Scholar 

  25. Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, Keppler BK, Marian B (2005) J Cancer Res Clin Oncol 131:101–110

    Article  PubMed  CAS  Google Scholar 

  26. Cauci S, Alessio E, Mestroni G, Quadrifoglio F (1987) Inorg Chim Acta 137:19–24

    Article  CAS  Google Scholar 

  27. Kelly JM, Feeney MM, Tossi AB, Lecomte JP, Kirsch-De Mesmaeker A (1990) Anticancer Drug Des 5:69–75

    PubMed  CAS  Google Scholar 

  28. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ (2005) J Med Chem 48:4161–4171

    Article  PubMed  CAS  Google Scholar 

  29. Dorcier A, Dyson PJ, Gossens C, Rothlisberger U, Scopelliti R, Tavernelli I (2005) Organometallics 24:2114–2123

    Article  CAS  Google Scholar 

  30. Scolaro C, Geldbach TJ, Rochat S, Dorcier A, Gossens A, Bergamo A, Cocchietto M, Tavernelli I, Sava G, Rothlisberger U, Dyson PJ (2006) Organometallics 25:756–765

    Article  CAS  Google Scholar 

  31. Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ (2006) Inorg Chem 45:9006–9013

    Article  PubMed  CAS  Google Scholar 

  32. Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ (2007) Dalton Trans 5065–5072

  33. Allardyce CS, Dyson PJ, Ellis DJ, Heath SL (2001) Chem Commun 1396–1397

  34. Reiber M, Reiber MS (2008) Cancer Biol Ther 7 (in press)

  35. Hayward RL, Schornagel QC, Tente R, Macpherson JS, Aird RE, Guichard S, Habtemariam A, Sadler P, Jodrell DI (2005) Cancer Chemother Pharmacol 55:577–583

    Article  PubMed  CAS  Google Scholar 

  36. Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP (2005) J Pharmacol Exp Ther 315:1403–1411

    Article  PubMed  CAS  Google Scholar 

  37. Perrone G, Vincenzi B, Santini D, Verzì A, Tonini G, Vetrani A, Rabitti C (2004) Cancer Lett 208:227–234

    Article  PubMed  CAS  Google Scholar 

  38. Garrido C, Galluzi L, Brunet M, Puig PE, Didelot C, Kroemer G (2006) Cell Death Differ 13:1423–1433

    Article  PubMed  CAS  Google Scholar 

  39. Montaner B, Perez-Tomas R (2002) Ann N Y Acad Sci 973:246–249

    Article  PubMed  CAS  Google Scholar 

  40. Frasca DR, Ciampa D, Emerson J, Umans RS, Clarke MJ (1996) Met Based Drugs 3:197–209

    Article  PubMed  CAS  Google Scholar 

  41. Dyson PJ, Sava G (2006) Dalton Trans 1929–1933

  42. Harris SL, Levine AJ (2005) Oncogene 24:2899–2908

    Article  PubMed  CAS  Google Scholar 

  43. Taylor WR, Stark GR (2001) Oncogene 20:1803–1815

    Article  PubMed  CAS  Google Scholar 

  44. Chen X, Zhang W, Gao YF, Su XQ, Zhai ZH (2002) Cell Res 12:229–233

    Article  PubMed  Google Scholar 

  45. Jaiswal AS, Bloom LB, Narayan S (2002) Oncogene 21:5912–5922

    Article  PubMed  CAS  Google Scholar 

  46. Coqueret O (2003) Trends Cell Biol 13:65–70

    Article  PubMed  CAS  Google Scholar 

  47. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J (2001) Nat Cell Biol 3:400–408

    Article  PubMed  CAS  Google Scholar 

  48. Kuo PC, Liu HF, Chao JI (2004) J Biol Chem 279:55875–55885

    Article  PubMed  CAS  Google Scholar 

  49. Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M (2006) Circ Res 98:1273–1281

    Article  PubMed  CAS  Google Scholar 

  50. Li Z, Pützer BM (2008) J Cell Mol Med 9999 (in press)

  51. Hengartner MO (2000) Nature 407:770–776

    Article  PubMed  CAS  Google Scholar 

  52. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z (1998) Genes Dev 12:2658–2663

    Article  PubMed  CAS  Google Scholar 

  53. Yoshida K, Miki Y (2005) Cell Cycle 4:777–779

    PubMed  CAS  Google Scholar 

  54. Ishikawa Y, Kusaka E, Enokido Y, Ikeuchi T, Hatanaka H (2003) Mol Cell Neurosci 24:451–459

    Article  PubMed  CAS  Google Scholar 

  55. Zu K, Hawthorn L, Ip C (2005) Mol Cancer Ther 4:43–50

    PubMed  CAS  Google Scholar 

  56. Liu J, Lin A (2005) Cell Res 151:36–42

    Article  Google Scholar 

Download references

Acknowledgments

The authors are indebted to the Department of Science and Technology, India, and the Indo Swiss Bilateral Research Initiative (EPFL) for funding this research. The support of the the Austrian Science Fund (C.G.H.; Schrödinger Fellowship J2613-N19) and of COST D39 is gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arindam Bhattacharyya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatterjee, S., Kundu, S., Bhattacharyya, A. et al. The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways. J Biol Inorg Chem 13, 1149–1155 (2008). https://doi.org/10.1007/s00775-008-0400-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00775-008-0400-9

Keywords

Navigation